These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28938493)

  • 1. Acute and Chronic Impact of Bariatric Surgery on Plasma LDL Cholesterol and PCSK9 Levels in Patients With Severe Obesity.
    Boyer M; Piché ME; Auclair A; Grenier-Larouche T; Biertho L; Marceau S; Hould FS; Biron S; Lebel S; Lescelleur O; Julien F; Martin J; Tchernof A; Carpentier AC; Poirier P; Arsenault BJ
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4023-4030. PubMed ID: 28938493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roux-en-Y gastric bypass, but not sleeve gastrectomy, decreases plasma PCSK9 levels in morbidly obese patients.
    Blanchard C; Ledoux S; Verhaegen A; Wargny M; Letessier E; Stepanian A; Huten N; Jacobi D; Krempf M; Le Bras M; Perrocheau Guillouche M; Arnaud L; Pichelin M; Van Gaal L; Cariou B; Le May C
    Diabetes Metab; 2020 Nov; 46(6):480-487. PubMed ID: 32032671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
    Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G
    J Clin Lipidol; 2018; 12(1):130-136. PubMed ID: 29103916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study.
    Xie W; Liu J; Wang W; Wang M; Qi Y; Zhao F; Sun J; Liu J; Li Y; Zhao D
    Int J Cardiol; 2016 Jul; 215():293-8. PubMed ID: 27128549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and chronic effect of bariatric surgery on circulating autotaxin levels.
    Bourgeois R; Piché ME; Auclair A; Grenier-Larouche T; Mitchell PL; Poirier P; Biertho L; Marceau S; Hould FS; Biron S; Lebel S; Lescelleur O; Julien F; Martin J; Tchernof A; Mathieu P; Carpentier AC; Arsenault BJ
    Physiol Rep; 2019 Mar; 7(5):e14004. PubMed ID: 30821134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between nesfatin-1 levels and metabolic improvements in severely obese patients who underwent biliopancreatic derivation with duodenal switch.
    St-Pierre DH; Martin J; Shimizu H; Tagaya Y; Tsuchiya T; Marceau S; Biertho L; Bastien M; Caron-Cantin SM; Simard S; Richard D; Cianflone K; Poirier P
    Peptides; 2016 Dec; 86():6-12. PubMed ID: 27681383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low levels of low-density lipoprotein-C associated with proprotein convertase subtilisin kexin 9 inhibition do not increase the risk of hemorrhagic transformation.
    Tran-Dinh A; Levoye A; Lambert G; Louedec L; Journé C; Meilhac O; Amarenco P
    Stroke; 2014 Oct; 45(10):3086-8. PubMed ID: 25123222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of long-term physical activity on PCSK9, high- and low-density lipoprotein cholesterol, and lipoprotein(a) levels: a prospective observational trial.
    Sponder M; Campean IA; Dalos D; Emich M; Fritzer-Szekeres M; Litschauer B; Bergler-Klein J; Graf S; Strametz-Juranek J
    Pol Arch Intern Med; 2017 Aug; 127(7-8):506-511. PubMed ID: 28607329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biliopancreatic diversion with duodenal switch improves insulin sensitivity and secretion through caloric restriction.
    Plourde CÉ; Grenier-Larouche T; Caron-Dorval D; Biron S; Marceau S; Lebel S; Biertho L; Tchernof A; Richard D; Carpentier AC
    Obesity (Silver Spring); 2014 Aug; 22(8):1838-46. PubMed ID: 24760439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and Chronic Impact of Biliopancreatic Diversion with Duodenal Switch Surgery on Plasma Lipoprotein(a) Levels in Patients with Severe Obesity.
    Després AA; Piché ME; Auclair A; Biertho L; Marceau S; Hould FS; Biron S; Lebel S; Lescelleur O; Julien F; Martin J; Tchernof A; Mathieu P; Poirier P; Arsenault BJ
    Obes Surg; 2020 Oct; 30(10):3714-3720. PubMed ID: 32666413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lipoprotein apheresis on PCSK9 levels.
    Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
    Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute caloric restriction counteracts hepatic bile acid and cholesterol deficiency in morbid obesity.
    Straniero S; Rosqvist F; Edholm D; Ahlström H; Kullberg J; Sundbom M; Risérus U; Rudling M
    J Intern Med; 2017 May; 281(5):507-517. PubMed ID: 28261926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients.
    Kappelle PJ; Lambert G; Dullaart RP
    Atherosclerosis; 2011 Feb; 214(2):432-5. PubMed ID: 21122860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
    Ridker PM; Rifai N; Bradwin G; Rose L
    Eur Heart J; 2016 Feb; 37(6):554-60. PubMed ID: 26508163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K; Park BS; Kim YW; Vaziri ND
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
    J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.